Fresenius Medical Care (ETR:FME) Receives a Downgrade
Jefferies & Company Inc. has downgraded shares of Fresenius Medical Care (ETR:FME) to a Underperform rating in analysts report issued to clients and investors on 17 December. The firm now has a EUR 64.00 target on shares. Jefferies & Company Inc.’s target would suggest a possibly downside of -15.78% from the current price of the stock.
From a total of 15 analysts covering Fresenius Medical Care (ETR:FME) stock, 8 rate it a ”Buy”, 0 a “Sell”, and 7 a ”Hold”. This means that 53% of the ratings are positive. The highest target price is €93 while the lowest target price is €68.70. The mean of all analyst targets is €82.19 with a 8.19% above today’s (€75.97) stock price. Fresenius Medical Care was the topic of 33 analyst reports since July 23, 2015 according to the firm StockzIntelligence Inc. Berenberg upgraded shares on December 5 to “Buy” rating. Credit Suisse upgraded shares to “Outperform” rating and €88 target share price in a report from a November 12. Bankhaus Lampe upgraded FME stock in a recent report from November 24 to “Buy” rating. Warburg Research maintained the rating on November 5. Warburg Research has a “Hold” rating and a €85 price target on shares. Finally, Bernstein upgraded the stock to “Outperform” rating in a report issued on a November 17.
The stock decreased 0.28% or EUR 0.21 on December 16, striking EUR 75.97. Approximately 485,619 shares of stock traded hands. Fresenius Medical Care AG & Co. KGaA (ETR:FME) has risen 6.00% since November 17, 2015 and is uptrending. It has outperformed by 8.62% the S&P500.
Fresenius Medical Care AG & Co. KGaA is a kidney dialysis company. It has 25.17 P/E ratio. The Firm provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services.